Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

130.45 +4.13 (+3.27%)

Streaming Delayed Price Updated: 10:24 AM EDT, Apr 14, 2026 Add to My Watchlist

Price and Volume

Volume	106,123
Open	126.32
Bid (Size)	130.13 (400)
Ask (Size)	130.60 (200)
Prev. Close	126.32
Today's Range	126.32 - 130.65
52wk Range	92.31 - 160.18
Shares Outstanding	100,100,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Top Affordable Growth Stock ↗

April 09, 2026

Via Chartmill

Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal

April 07, 2026

In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive...

Via MarketMinute

Performance

YTD	-7.2%	-7.2%
1 Month	+0.5%	+0.5%
3 Month	-1.7%	-1.7%
6 Month	-5.0%	-5.0%
1 Year	+37.5%	+37.5%

More News

Neurocrine Biosciences (NBIX): A New Era in Neuroscience and Endocrinology

April 07, 2026

Via Finterra

Neurocrine Biosciences Inc. (NASDAQ:NBIX) Presents a Strong Growth and Technical Setup ↗

March 25, 2026

Via Chartmill

Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents a Compelling Case as a Quality Value Stock ↗

March 20, 2026

Via Chartmill

Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Top GARP Pick with Strong Growth and a Reasonable Price ↗

March 13, 2026

Via Chartmill

Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Fundamentals and a Bullish Chart Pattern ↗

February 24, 2026

Via Chartmill

Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit

April 07, 2026

Via Finterra

Wall Street Holds Its Ground While Trump's Iran Deadline Ticks Down ↗

April 07, 2026

Via Chartmill

Why Soleno Therapeutics Stock Rocketed Higher on Monday ↗

April 06, 2026

Via The Motley Fool

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Soleno Therapeutics, Inc. (Nasdaq – SLNO), Affinity Bancshares, Forian, Inc. (Nasdaq – FORA), Janus Henderson Group plc (NYSE - JHG)

April 06, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

Neurocrine Biosciences Inc (NASDAQ:NBIX) Fits the GARP Strategy with Strong Growth and Reasonable Valuation ↗

February 17, 2026

Via Chartmill

Neurocrine Biosciences Inc (NASDAQ:NBIX) Screens as a Compelling Value Investment ↗

February 13, 2026

Via Chartmill

Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar

April 06, 2026

Via MarketMinute

Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential ↗

March 23, 2026

Via The Motley Fool

The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE)

March 10, 2026

Via Finterra

Neurocrine Biosciences Inc (NASDAQ:NBIX) Reports Q4 2025 Earnings Miss Amid Strong Annual Sales Growth ↗

February 11, 2026

Via Chartmill

Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents a Compelling Mix of Strong Fundamentals and Bullish Technical Setup ↗

January 31, 2026

Via Chartmill

Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data ↗

February 19, 2026

Via The Motley Fool

Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead ↗

February 19, 2026

Via The Motley Fool

This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition ↗

February 19, 2026

Via The Motley Fool

Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Prime Affordable Growth Stock ↗

January 23, 2026

Via Chartmill

CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale ↗

February 19, 2026

Via The Motley Fool

BrightSpring Stock Up 86% as Braidwell Takes $45 Million Stake in Healthcare Services Provider ↗

February 19, 2026

Via The Motley Fool

Neurocrine (NBIX) Q4 2025 Earnings Call Transcript ↗

February 11, 2026

Via The Motley Fool

Frequently Asked Questions

Is Neurocrine Biosciences, Inc. - Common Stock publicly traded?

Yes, Neurocrine Biosciences, Inc. - Common Stock is publicly traded.

What exchange does Neurocrine Biosciences, Inc. - Common Stock trade on?

Neurocrine Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Neurocrine Biosciences, Inc. - Common Stock?

The ticker symbol for Neurocrine Biosciences, Inc. - Common Stock is NBIX on the Nasdaq Stock Market

What is the current price of Neurocrine Biosciences, Inc. - Common Stock?

The current price of Neurocrine Biosciences, Inc. - Common Stock is 130.45

When was Neurocrine Biosciences, Inc. - Common Stock last traded?

The last trade of Neurocrine Biosciences, Inc. - Common Stock was at 04/14/26 10:24 AM ET

What is the market capitalization of Neurocrine Biosciences, Inc. - Common Stock?

The market capitalization of Neurocrine Biosciences, Inc. - Common Stock is 13.06B

How many shares of Neurocrine Biosciences, Inc. - Common Stock are outstanding?

Neurocrine Biosciences, Inc. - Common Stock has 13B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.